SLC6A1

Sodium- and chloride-dependent GABA transporter 1 · P30531 · SLC6A1 on Sugi Atlas →

22,784 patent compounds predicted against SLC6A1, 8,258 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL676997 SCHEMBL676997 1.00 15/20
SCHEMBL676998 SCHEMBL676998 1.00 15/20
Tiagabine Tiagabine (SCHEMBL34653) 1.00 10/20
Tiagabine Tiagabine (SCHEMBL342814) 1.00 10/20
Tiagabine Tiagabine (SCHEMBL677642) 0.70 10/20
SCHEMBL262828 SCHEMBL262828 0.49 9/20
Tiagabine Tiagabine (SCHEMBL41860) 1.00 8/20
Tiagabine Tiagabine (SCHEMBL1462478) 0.57 8/20
Ticarcillin Ticarcillin (SCHEMBL1462788) 0.54 8/20
SCHEMBL262183 SCHEMBL262183 0.45 5/20
SCHEMBL1225755 SCHEMBL1225755 0.77 4/20
SCHEMBL44023 SCHEMBL44023 0.69 4/20
SCHEMBL45098 SCHEMBL45098 0.57 4/20
SCHEMBL1249676 SCHEMBL1249676 0.57 4/20
SCHEMBL1249678 SCHEMBL1249678 0.57 4/20
SCHEMBL1249680 SCHEMBL1249680 0.57 4/20
SCHEMBL1251294 SCHEMBL1251294 0.57 4/20
SCHEMBL1251296 SCHEMBL1251296 0.57 4/20
SCHEMBL764125 SCHEMBL764125 0.52 4/20
SCHEMBL40181 SCHEMBL40181 0.50 4/20

Clinical trials — most relevant to SLC6A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Kuvan on Melatonin Secretion PHASE4COMPLETED
Computational Assessment of GABA Receptor Modulation in PTSD PHASE4RECRUITING
The Effects of Levetiracetam on Alcohol Dependent Subjects PHASE4COMPLETED
Treating Schizophrenia by Correcting Abnormal Brain Development PHASE3ACTIVE_NOT_RECRUITING
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia PHASE2/PHASE3COMPLETED
Glutamate Inhibitors in Glioblastoma PHASE1/PHASE2RECRUITING
Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome PHASE2RECRUITING
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Effects of Baclofen on Presynaptic Inhibition in Humans PHASE2WITHDRAWN
Vigabatrin for Treatment of Cocaine Dependence PHASE2COMPLETED
Pilot Study of Bumetanide for Newborn Seizures PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy EARLY_PHASE1ACTIVE_NOT_RECRUITING
MEG Study of Acute STX209 Effects in ASD EARLY_PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle nanCOMPLETED
Pharmacokinetics Study of Gamma-aminobutyric Acid nanCOMPLETED
GABA Biomarkers in Dravet Syndrome nanRECRUITING
Analgesic Effect of Oxytocin Receptor Modulation nanCOMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI nanCOMPLETED
PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency nanCOMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder nanUNKNOWN
Effects of Sulfasalazine on BOLD Response to Alcohol Cues nanCOMPLETED
A Study of Cases with Abnormal Serum Ammonia in Neonate and Children Attending Assiut University Children Hospital nanNOT_YET_RECRUITING
Clinical-Genetic Variation in GABA/Alcohol Sensitivity nanCOMPLETED
Mechanisms of Human Plasticity in the Human System nanCOMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC6A1 binder may also engage these)

ProteinNameSimilarity
P48057 1.000 P48057 →
SLC6A13 Sodium- and chloride-dependent GABA transporter 2 1.000 landscape →
B4JMC1 1.000 B4JMC1 →
Q9MZ34 1.000 Q9MZ34 →
P31650 1.000 P31650 →
P51905 1.000 P51905 →
Q00589 1.000 Q00589 →
Q9JMA9 1.000 Q9JMA9 →
Q9XT49 1.000 Q9XT49 →
Q8VDB9 1.000 Q8VDB9 →
Q7K4Y6 1.000 Q7K4Y6 →
Q28039 1.000 Q28039 →
Q8VBW1 1.000 Q8VBW1 →
SLC6A3 Sodium-dependent dopamine transporter 0.999 landscape →
P31649 0.999 P31649 →
Q9W4C5 0.999 Q9W4C5 →
P31646 0.998 P31646 →
SLC6A4 Sodium-dependent serotonin transporter 0.998 landscape →
B4MEG2 0.998 B4MEG2 →
O35899 0.998 O35899 →
SLC6A12 Sodium- and chloride-dependent betaine transporter 0.997 landscape →
Q29GB8 0.997 Q29GB8 →
SLC6A11 Sodium- and chloride-dependent GABA transporter 3 0.997 landscape →
Q2A865 0.997 Q2A865 →
P23978 0.997 P23978 →
P51143 0.996 P51143 →
Q9MYX0 0.996 Q9MYX0 →
P31648 0.996 P31648 →
P31652 0.996 P31652 →
SLC6A6 Sodium- and chloride-dependent taurine transporter 0.996 landscape →